Short Interest in SAB Biotherapeutics, Inc. (NASDAQ:SABSW) Declines By 45.1%

SAB Biotherapeutics, Inc. (NASDAQ:SABSW) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 2,800 shares, a decrease of 45.1% from the January 15th total of 5,100 shares. Based on an average daily trading volume, of 33,500 shares, the short-interest ratio is presently 0.1 days.

SAB Biotherapeutics Stock Up 3.0 %

SABSW stock traded up $0.00 during trading on Thursday, reaching $0.03. 5,001 shares of the stock were exchanged, compared to its average volume of 52,950. SAB Biotherapeutics has a twelve month low of $0.01 and a twelve month high of $0.19. The firm’s 50 day moving average is $0.07 and its 200 day moving average is $0.05.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.